Oral Therapy, VK2809, Shows Potential in Treating NASH-related Fibrosis in Early Study
News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis
The investigative therapy VK2809 showed promising results in an animal study of non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease, Viking Therapeutics, its developer, announced. The treatment’s safety and efficacy is ... Read more